SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Nvidia Options Price in $280 Billion Earnings Swing 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Trump Buys SpaceX Shares After Record IPO 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Add as a preferred source on Google
PLANO, Texas, April 23, 2018 -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the first quarter ended March 31, 2018 on Wednesday, May 2, 2018 after market close.
Nuvectra will hold a conference call on Wednesday, May 2, 2018, at 4:30pm ET to discuss the results. The dial-in numbers are (844) 882-7830 for domestic callers and (574) 990-9704 for international callers. The conference ID is 2896392. A live webcast of the conference call will be available on the investor relations section of the Company’s website at http://investors.nuvectramed.com/.
A replay of the call will be available starting on May 2, 2018 through May 9, 2018. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and enter access code 2896392. The webcast will be available in the investor relations section of the Company’s website for 90 days following the completion of the call.
About Nuvectra Corporation
NuvectraTM is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic intractable pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other indications such as sacral neuromodulation (SNM) for the treatment of overactive bladder, and deep brain stimulation (DBS) for the treatment of Parkinson’s Disease. In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.
Company Contacts:
Nuvectra Corporation
Walter Berger, COO & CFO
(214) 474-3102
[email protected]
Investor Contacts:
The Ruth Group
Tram Bui / Brian Johnston
(646) 536-7035 / 7028
[email protected]
